Bayer
Bayer enters $252 million Dimension deal
June 24, 2014Manufacturing and Production, Research and Development, Sales and Marketing Bayer, dimension, haemophilia, haemophilia a, therapeutics
Bayer HealthCare will pay up to $252 million to Dimension Therapeutics in a deal which sees the companies collaborate on …
Bayer announces more changes at the top
June 6, 2014Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Dieter Weinand, Otsuka, dekkers, healthcare
US-based president at Japanese drugmaker Otsuka, Dieter Weinand, is to join Bayer Healthcare Pharmaceuticals as the new head of its …
Bayer’s chief executive to step down in 2016
June 4, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Germany, Marijn Dekkers
Marijn Dekkers the chief executive of German pharma firm Bayer has set his departure date to the end of 2016. …
Bayer concludes $14bn Merck consumer care takeover
May 7, 2014Sales and Marketing Bayer, Merck, OTC, consumer care, merger
Bayer has confirmed its acquisition of US firm Merck’s over-the-counter (OTC) portfolio in a deal worth $14 billion. The arrangement …
Bayer to make $14 bn move for Merck unit
May 2, 2014Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Boehringer, Merck, Novartis, Reckitt Benckiser, claritin, reuters
Bayer is in talks with Merck & Co to buy its consumer business and is willing to pay $14 billion …
NICE says ‘no’ to Xofigo
March 24, 2014Sales and Marketing Bayer, CDF, NHS, NICE, abiraterone, prostate, xofigo
NICE has dealt Bayer a severe blow by not approving prostate cancer drug Xofigo for use on the NHS in …
Xarelto lift for Bayer
March 3, 2014Manufacturing and Production, Sales and Marketing Bayer, Eylea, Stivarga, Xarelto, blood thinner, xofigo
Bayer Group says sales of its blood thinner Xarelto will be higher than it had predicted, with peak annual sales …
Bayer ‘disappointed’ with FDA
February 18, 2014Sales and Marketing ACS, Bayer, Xarelto, blood, rivaroxaban
Bayer HealthCare has expressed its dismay after the Food and Drug Administration once again rejected further indications for the company’s …
Bayer and Regeneron to co-develop wet AMD antibody
January 14, 2014Research and Development, Sales and Marketing Bayer, Eylea, Regeneron, pdgfr-beta, wet AMD
Bayer and Regeneron are co-developing an antibody to the Platelet Derived Growth Factor Receptor Beta (PDGFR-beta) as a combination therapy …
Board changes at Bayer
December 23, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, malik
Bayer has appointed Kemal Malik to its management board with responsibility for innovation, succeeding Wolfgang Plischke who is retiring. Bayer …
Bayer in $2.9 billion Algeta deal
December 19, 2013Sales and Marketing Algeta, Bayer, oncology, xofigo
Bayer and Algeta have decided to avoid the usual M&A dance, opting instead to agree a business deal with little …
Bayer targets Norway’s Algeta
November 27, 2013Sales and Marketing Algeta, Bayer, oncology, xofigo
Bayer HealthCare is in the market to buy Norwegian oncology specialist Algeta. The German pharma group has made a bid …
US regulator shows Nexavar green light
November 25, 2013Sales and Marketing Bayer, Cancer, FDA, Nexavar, Onyx, thyroid
The FDA has extended the indication of liver and kidney cancer pill Nexavar to treat late-stage differentiated thyroid cancer. It …
Bayer cancer drug gets EU approval
November 18, 2013Sales and Marketing Bayer, CHMP, EU, Xtandi, Zytiga, xofigo
Bayer’s prostate cancer treatment Xofigo has been shown the green light by the European Commission. Xofigo (radium Ra 223 dichloride) …
Bayer submits Eylea in EU for DME
November 8, 2013Sales and Marketing Bayer, DME, EMA, Eylea, FDA
Bayer HealthCare is seeking to extend the licence of its VEGF Trap-Eye, which is already marketed as Eylea in various …
Latest content
